Full Article
Evidence Summary
What is an Evidence Summary?
Key messages from scientific research that's ready to be acted on
Got It, Hide thisFor people with atrial fibrillation, new “blood thinners” (factor Xa inhibitors) reduce strokes and clots more than warfarin
Bruins Slot KMH, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013;8:CD008980.
Review question
How effective and safe are factor Xa inhibitors for the prevention of cerebral embolism (strokes) or systemic embolic events in people with atrial fibrillation?
Background
Atrial fibrillation is a common type of irregular heartbeat. It can lead to small clots forming in the heart. Clots can then flow from the heart to block an artery in the brain (cerebral embolism causing a stroke) or other organ (systemic embolism of the heart—causing a heart attack—or the legs—causing gangrene).
Management of atrial fibrillation aims at reducing symptoms and preventing blood clotting. An adverse effect of preventing clots is abnormal bleeding.
For decades, anticoagulant treatment with vitamin K antagonists such as warfarin (Coumadin) has been the therapy of choice for most people with atrial fibrillation.
Factor Xa inhibitors—a new class of anticoagulants—seem to have some advantages over vitamin K antagonists.
How the review was done
This summary is based on a systematic review of 10 randomized controlled trials directly comparing warfarin with factor Xa inhibitors. Publication period was 2008 to 2013.
Studies involved 42,084 people. Age ranged from 18 to 75 years. At least 50% of participants were followed up for between 12 weeks and 1.9 years
Factor Xa inhibitors assessed were apixaban, betrixaban, darexaban, edoxaban, idraparinux, and rivaroxaban.
Outcomes included strokes, embolism in other organs, major bleeding, intracranial hemorrhage, and death from all causes.
What the researchers found
Compared with warfarin, factor Xa inhibitors
- reduced the number of strokes and systemic embolic events by 22% (7 fewer events per 1,000 people treated).
- reduced the number of strokes by 26% (7 fewer events per 1,000 people treated).
- reduced the number of major bleeds by 15% (7 fewer events per 1,000 people treated). This evidence is less strong due to variation of effect across trials.
- reduced the number of intracranial hemorrhages by 45% (6 fewer events per 1,000 people treated).
- reduced the number of deaths from any cause by 18% (6 fewer events per 1,000 people treated).
Conclusion
For people with atrial fibrillation, anticoagulant treatment with factor Xa inhibitors reduces strokes and systemic embolic events compared with warfarin and also reduces the risk of bleeding.
Glossary
Medications that suppress, delay, or prevent blood clots. Anticoagulants (also referred to as "blood thinners") are used to treat circulatory blockages.
Bleeding inside the skull.
Studies where people are assigned to one of the treatments purely by chance.
A comprehensive evaluation of the available research evidence on a particular topic.
Related Evidence Summaries
-
Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
Cochrane Database of Systematic Reviews (2017)
-
Providing patients and their care providers with information about cardiovascular disease risk may help with prevention measures
BMJ Open (2015)
-
Dietary fibre for the primary prevention of cardiovascular disease
Cochrane Database of Systematic Reviews (2016)
